文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

SPIOMET4HEALTH——生活方式干预联合螺内酯、吡格列酮和二甲双胍固定剂量复方(SPIOMET)治疗青少年及年轻女性多囊卵巢综合征的有效性、耐受性和安全性:多中心、随机、双盲、安慰剂对照、四臂、平行组、II期临床试验研究方案

SPIOMET4HEALTH-efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a multicentre, randomised, double-blind, placebo-controlled, four-arm, parallel-group, phase II clinical trial.
PubMed 文献 · Trials · 2023-09-15

多囊卵巢综合征(PCOS)影响全球5-10%的青少年及年轻女性,目前尚无获批药物。本II期试验拟从欧洲7个临床中心招募364例PCOS患者,随机1:1:1:1分为安慰剂组、吡格列酮组、螺内酯+吡格列酮组和螺内酯+吡格列酮+二甲双胍组,在生活方式指导基础上每日一次口服一片,治疗12个月、随访6个月,主要终点为治疗期间及治疗后排卵率。

要点

  • PCOS影响全球5-10%的青少年及年轻女性,目前无获批药物。
  • SPIOMET为螺内酯、吡格列酮和二甲双胍的固定低剂量复方单片。
  • 本II期试验拟随机364例,主要终点为治疗期间及治疗后排卵率。

核心结论

  • 本研究将首次以随机、双盲、安慰剂对照方式评估SPIOMET联合生活方式干预治疗早期PCOS的有效性、耐受性和安全性。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照、四臂、平行组、II期临床试验。
  • 拟从欧洲7个临床中心招募364例合格PCOS患者,按1:1:1:1随机分为安慰剂组、吡格列酮组、螺内酯+吡格列酮组和螺内酯+吡格列酮+二甲双胍组。
  • 活性治疗12个月,内容为生活方式指导加每日一次一片(晚餐时服用);治疗后随访6个月。

主要发现

  • 主要终点为治疗期间及治疗后的排卵率。
  • 次要终点包括临床特征(多毛症、月经规律性)、内分泌代谢指标(雄激素、血脂、胰岛素、炎症标志物)、表观遗传标志物、影像学数据(颈动脉内中膜厚度、体成分、腹部脂肪分布、肝脏脂肪)、安全性特征、药物依从性、耐受性和可接受性以及研究参与者的生活质量。
  • 将依次检验SPIOMET、螺内酯+吡格列酮和吡格列酮相对于安慰剂的优效性,若存在则随后检验SPIOMET相对于吡格列酮的优效性,若仍存在则最终检验相对于螺内酯+吡格列酮的优效性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Polycystic ovary syndrome (PCOS) is the most prevalent, chronic endocrine-metabolic disorder of adolescents and young women (AYAs), affecting 5-10% of AYAs worldwide. There is no approved pharmacological therapy for PCOS. Standard off-label treatment with oral contraceptives (OCs) reverts neither the underlying pathophysiology nor the associated co-morbidities. Pilot studies have generated new insights into the pathogenesis of PCOS, leading to the development of a new treatment consisting of a fixed, low-dose combination of two so-called insulin sensitisers [pioglitazone (PIO), metformin (MET)] and one mixed anti-androgen and anti-mineralocorticoid also acting as an activator of brown adipose tissue [spironolactone (SPI)], within a single tablet (SPIOMET). The present trial will evaluate the efficacy, tolerability and safety of SPIOMET, on top of lifestyle measures, for the treatment of PCOS in AYAs. METHODS: In this multicentre, randomised, double-blind, placebo-controlled, four-arm, parallel-group, phase II clinical trial, AYAs with PCOS will be recruited from 7 clinical centres across Europe. Intention is to randomise a total of 364 eligible patients into four arms (1:1:1:1): Placebo, PIO, SPI + PIO (SPIO) and SPI + PIO + MET (SPIOMET). Active treatment over 12 months will consist of lifestyle guidance plus the ingestion of one tablet daily (at dinner time); post-treatment follow-up will span 6 months. Primary endpoint is on- and post-treatment ovulation rate. Secondary endpoints are clinical features (hirsutism, menstrual regularity); endocrine-metabolic variables (androgens, lipids, insulin, inflammatory markers); epigenetic markers; imaging data (carotid intima-media thickness, body composition, abdominal fat partitioning, hepatic fat); safety profile; adherence, tolerability and acceptability of the medication; and quality of life in the study participants. Superiority (in this order) of SPIOMET, SPIO and PIO will be tested over placebo, and if present, subsequently the superiority of SPIOMET versus PIO, and if still present, finally versus SPIO. DISCUSSION: The present study will be the first to evaluate-in a randomised, double-blind, placebo-controlled way-the efficacy, tolerability and safety of SPIOMET treatment for early PCOS, on top of a lifestyle intervention. TRIAL REGISTRATION: EudraCT 2021-003177-58. Registered on 22 December 2021. https://www.clinicaltrialsregister.eu/ctr-search/search?query=%092021-003177-58 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Garcia-Beltran C, Malpique R, Andersen MS, et al. SPIOMET4HEALTH-efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a multicentre, randomised, double-blind, placebo-controlled, four-arm, parallel-group, phase II clinical trial. Trials. 2023. PMID: 37715279. doi:10.1186/s13063-023-07593-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。